Multi-state survival analysis in cost-effectiveness studies: the case of capecitabine versus docetaxel in metastatic breast cancer (mbc) for a private payer in Brazil

被引：0
|
作者：
Santos, E. A. [1 ]
Marques, R. M. [2 ]
机构：
[1] Roche Brazil, Sao Paulo, Brazil
[2] Hosp Sirio Libanes, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)65219-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A341 / A341
页数：1
相关论文
共 50 条
  • [31] UK cost-effectiveness analyses of docetaxel versus generic paclitaxel once weekly and nab-paclitaxel in patients with locally advanced or metastatic breast cancer (MBC) progressed after anthracycline chemotherapy
    Benedict, A.
    Cameron, D.
    Corson, H.
    Jones, S.
    VALUE IN HEALTH, 2007, 10 (06) : A336 - A336
  • [32] COST-EFFECTIVENESS ANALYSIS OF NOVEL THERAPIES FOR HER2+METASTATIC BREAST CANCER: [FAM-] TRASTUZUMAB DERUXTECAN VERSUS TUCATINIB TRASTUZUMAB AND CAPECITABINE COMBINATION
    Vondeling, G.
    Palaka, E.
    Livings, C.
    Naik, J.
    Sullivan, W.
    VALUE IN HEALTH, 2020, 23 : S433 - S434
  • [33] Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naive prostate cancer (mHNPC)
    Ramamurthy, Chethan
    Correa, Andres F.
    Handorf, Elizabeth A.
    Beck, J. Robert
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective
    P.-F Zhang
    F. Wen
    J. Zhou
    J.-X. Huang
    K.-X. Zhou
    Q.-J. Wu
    X.-Y. Wang
    M.-X. Zhang
    W.-T. Liao
    Q. Li
    Clinical and Translational Oncology, 2020, 22 : 103 - 110
  • [35] Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective
    Zhang, P. -F
    Wen, F.
    Zhou, J.
    Huang, J. -X.
    Zhou, K. -X.
    Wu, Q. -J.
    Wang, X. -Y.
    Zhang, M. -X.
    Liao, W. -T.
    Li, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (01): : 103 - 110
  • [36] Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling
    Williams, Claire
    Lewsey, James D.
    Mackay, Daniel F.
    Briggs, Andrew H.
    MEDICAL DECISION MAKING, 2017, 37 (04) : 427 - 439
  • [37] Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese PerspectiveDoxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
    Peng Liubao
    Wan Xiaomin
    Tan Chongqing
    Jon Karnon
    Chen Gannong
    Li Jianhe
    Cui Wei
    Luo Xia
    Cao Junhua
    PharmacoEconomics, 2009, 27 : 873 - 886
  • [38] Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective
    Chiang, Chi Leung
    So, Tsz Him
    Lam, Tai Chung
    Choi, Horace C. W.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (01) : 108 - 115
  • [39] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS DOCETAXEL FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN BELGIUM
    Moeremans, K.
    Van Bellinghen, L.
    De Celle, T.
    Quintens, B.
    Paracha, N.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [40] Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective
    Chi Leung Chiang
    Tsz Him So
    Tai Chung Lam
    Horace C. W. Choi
    Prostate Cancer and Prostatic Diseases, 2020, 23 : 108 - 115
12345